These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 26178345)

  • 1. Practice-Changing Findings.
    Fidler MJ
    Oncology (Williston Park); 2015 Jul; 29(7):502-4. PubMed ID: 26178345
    [No Abstract]   [Full Text] [Related]  

  • 2. Checkpoint inhibitor shows promise in smokers.
    Cancer Discov; 2013 Dec; 3(12):OF8. PubMed ID: 24327717
    [No Abstract]   [Full Text] [Related]  

  • 3. Recovery from carcinomatous meningitis by erlotinib.
    Ohara G; Kagohashi K; Kurishima K; Kawaguchi M; Nakayama H; Satoh H
    Onkologie; 2011; 34(7):394-5. PubMed ID: 21734429
    [No Abstract]   [Full Text] [Related]  

  • 4. [Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
    Mairovitz A; Staub E; Le Floch H; Rivière F; Bonnichon A; Margery J; Vaylet F
    Rev Pneumol Clin; 2009 Oct; 65(5):318-21. PubMed ID: 19878809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
    Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
    Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
    [No Abstract]   [Full Text] [Related]  

  • 6. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
    Zhang PL; Chen L
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890
    [No Abstract]   [Full Text] [Related]  

  • 7. Significant drug interaction: phenytoin toxicity due to erlotinib.
    Grenader T; Gipps M; Shavit L; Gabizon A
    Lung Cancer; 2007 Sep; 57(3):404-6. PubMed ID: 17383767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK inhibitors in lung cancer.
    Heath E
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):649-50. PubMed ID: 20040904
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted kinase inhibitors in lung cancer: from EGFR to patients.
    Apolone G; La Vecchia C; Garattini S
    Eur J Cancer; 2006 Jan; 42(2):124-5. PubMed ID: 16324837
    [No Abstract]   [Full Text] [Related]  

  • 10. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
    Popat S; Hughes S; Papadopoulos P; Wilkins A; Moore S; Priest K; Meehan L; Norton A; O'Brien M
    Lung Cancer; 2007 Apr; 56(1):135-7. PubMed ID: 17157952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
    Engelman JA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4637-40. PubMed ID: 17671156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immuno-Oncology therapeutic principles in lung and renal cell carcinoma].
    Wolf J; Grünwald V
    Oncol Res Treat; 2014; 37 Suppl 4():10-3. PubMed ID: 25301191
    [No Abstract]   [Full Text] [Related]  

  • 14. [TARCEVA Clinical Registry].
    Skricková J; Pesek M; Zatloukal P; Kolek V; Salajka F; Koubková L; Krejcí J; Tomísková M; Grygárková Y; Havel L; Hrnciarik M; Skalová B; Stícha M
    Klin Onkol; 2010; 23(5):361-3. PubMed ID: 21061685
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
    Zhang J; Yu J; Sun X; Meng X
    Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
    Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 18. c-Met inhibition.
    Salgia R
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):823-4. PubMed ID: 17143251
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
    Jamal-Hanjani M; Spicer J
    Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib (xalkori) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.